Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...

Vor Bio is the latest cell therapy company to reach the end of the road. The biotech is immediately winding down clinical and manufacturing operations and laying off almost all staff. Around 95% of ...

Less than two months after Vor Bio telegraphed a strategic review, the former cell therapy biotech has made a surprise comeback with a potential $4 billion deal licensing a China-made autoimmune asset ...

Shares of Vor Bio VOR have soared a staggering 265.5% in the past week compared with the industry’s rise of 0.8%. Last week, the company entered a licensing agreement with RemeGen, a China-based ...

) has been revised to $36.46 / share. This is an increase of 2,942.55% from the prior estimate of $1.20 dated September 10, 2025. The price target is an average of many targets provided by analysts.

Vor Biopharma is developing novel cell therapies for AML, with trem-cel showing early promise in clinical trials but facing significant funding challenges. Trem-cel aims to enhance relapse-free ...

Vor Bio has handed Dallan Murray a swift return to the workforce. Weeks after being let go by Sarepta Therapeutics, Murray has landed the chief commercial officer post in Vor’s new-look C-suite.

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest update is out from Vor ...

Vor Biopharma Inc. (NASDAQ:VOR) saw its stock climb Thursday following a strategic licensing agreement and a major capital raise to support its push into autoimmune therapies. The developments mark a ...